| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.
|
J Allergy Clin Immunol
|
2003
|
5.43
|
|
2
|
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.
|
Pediatrics
|
2004
|
3.71
|
|
3
|
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
|
AIDS
|
2008
|
2.35
|
|
4
|
Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae.
|
Pediatrics
|
2002
|
2.08
|
|
5
|
A behavioral and cognitive profile of clinically stable HIV-infected children.
|
Pediatrics
|
2006
|
1.78
|
|
6
|
Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia.
|
AIDS Res Hum Retroviruses
|
2008
|
1.52
|
|
7
|
Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
|
Clin Infect Dis
|
2004
|
1.44
|
|
8
|
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.
|
AIDS
|
2012
|
1.39
|
|
9
|
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children.
|
Pediatrics
|
2005
|
1.39
|
|
10
|
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.
|
Pediatr Infect Dis J
|
2005
|
1.34
|
|
11
|
Six year multicenter surveillance of invasive pneumococcal infections in children.
|
Pediatr Infect Dis J
|
2002
|
1.28
|
|
12
|
In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.
|
AIDS Patient Care STDS
|
2011
|
1.26
|
|
13
|
Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.
|
AIDS Behav
|
2010
|
1.26
|
|
14
|
Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection.
|
J Infect Dis
|
2007
|
1.26
|
|
15
|
Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy.
|
Arch Pediatr Adolesc Med
|
2002
|
1.25
|
|
16
|
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
|
Vaccine
|
2008
|
1.23
|
|
17
|
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
|
Pediatr Infect Dis J
|
2009
|
1.20
|
|
18
|
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
|
J Infect Dis
|
2005
|
1.18
|
|
19
|
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.
|
HIV Med
|
2011
|
1.14
|
|
20
|
Streptococcus pneumoniae infections in the neonate.
|
Pediatrics
|
2003
|
1.14
|
|
21
|
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
|
Pediatr Infect Dis J
|
2003
|
1.11
|
|
22
|
Invasive pneumococcal infections in children with asplenia.
|
Pediatr Infect Dis J
|
2002
|
1.09
|
|
23
|
Quantification of human immunodeficiency virus type 1 proviral DNA by using TaqMan technology.
|
J Clin Microbiol
|
2002
|
1.08
|
|
24
|
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
|
Pediatrics
|
2007
|
1.08
|
|
25
|
Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review.
|
J Clin Microbiol
|
2003
|
1.07
|
|
26
|
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
|
Pediatr Infect Dis J
|
2010
|
1.05
|
|
27
|
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
|
Antivir Ther
|
2011
|
1.02
|
|
28
|
Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.
|
J Infect Dis
|
2012
|
1.00
|
|
29
|
Indirect protection of adults from rotavirus by pediatric rotavirus vaccination.
|
Clin Infect Dis
|
2013
|
0.99
|
|
30
|
Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.
|
BMC Infect Dis
|
2012
|
0.99
|
|
31
|
A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
|
J Infect Dis
|
2005
|
0.99
|
|
32
|
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
|
AIDS
|
2008
|
0.96
|
|
33
|
Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy.
|
Rev Med Virol
|
2014
|
0.95
|
|
34
|
Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.
|
AIDS
|
2011
|
0.94
|
|
35
|
Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda.
|
AIDS
|
2013
|
0.94
|
|
36
|
White matter microstructure among youth with perinatally acquired HIV is associated with disease severity.
|
AIDS
|
2015
|
0.92
|
|
37
|
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
|
PLoS One
|
2013
|
0.91
|
|
38
|
Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube.
|
HIV Clin Trials
|
2004
|
0.90
|
|
39
|
Early viral suppression improves neurocognitive outcomes in HIV-infected children.
|
AIDS
|
2015
|
0.89
|
|
40
|
Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
|
Pediatrics
|
2008
|
0.89
|
|
41
|
Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
|
Antimicrob Agents Chemother
|
2008
|
0.89
|
|
42
|
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
|
Vaccine
|
2013
|
0.87
|
|
43
|
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
|
Antimicrob Agents Chemother
|
2011
|
0.87
|
|
44
|
B-type natriuretic peptide and heart failure in patients with ventricular septal defect: a pilot study.
|
Pediatr Cardiol
|
2009
|
0.87
|
|
45
|
Pneumococcal endocarditis in children.
|
Clin Infect Dis
|
2004
|
0.86
|
|
46
|
Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots.
|
Bioanalysis
|
2015
|
0.86
|
|
47
|
Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.
|
Pediatr Infect Dis J
|
2012
|
0.84
|
|
48
|
The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
|
Pediatrics
|
2009
|
0.84
|
|
49
|
Default Mode Connectivity in Youth With Perinatally Acquired HIV.
|
Medicine (Baltimore)
|
2015
|
0.84
|
|
50
|
Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
|
Pediatrics
|
2008
|
0.83
|
|
51
|
Higher incidence of perineal community acquired MRSA infections among toddlers.
|
BMC Pediatr
|
2011
|
0.83
|
|
52
|
The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
|
Pediatrics
|
2005
|
0.83
|
|
53
|
The role of protease inhibitor therapy in children with HIV infection.
|
Paediatr Drugs
|
2002
|
0.83
|
|
54
|
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
|
Pharmacotherapy
|
2004
|
0.82
|
|
55
|
Balancing the upside and downside of antiretroviral therapy in children.
|
JAMA
|
2005
|
0.82
|
|
56
|
Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older children.
|
J Med Virol
|
2011
|
0.82
|
|
57
|
Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART.
|
J Virol
|
2004
|
0.82
|
|
58
|
Is noma neonatorum a presentation of ecthyma gangrenosum in the newborn?
|
Pediatr Infect Dis J
|
2002
|
0.81
|
|
59
|
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
|
Pediatr Infect Dis J
|
2005
|
0.81
|
|
60
|
Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.
|
Clin Infect Dis
|
2016
|
0.81
|
|
61
|
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
|
Int J Antimicrob Agents
|
2008
|
0.79
|
|
62
|
Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies.
|
Clin Diagn Lab Immunol
|
2002
|
0.79
|
|
63
|
Computerized vital signs analysis and late onset infections in extremely low gestational age infants.
|
J Perinat Med
|
2016
|
0.78
|
|
64
|
Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia.
|
Vaccine
|
2008
|
0.78
|
|
65
|
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
|
Pediatr Infect Dis J
|
2009
|
0.77
|
|
66
|
Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012.
|
AIDS
|
2015
|
0.77
|
|
67
|
Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.
|
Antivir Ther
|
2002
|
0.77
|
|
68
|
Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis.
|
Pediatr Infect Dis J
|
2011
|
0.76
|
|
69
|
Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children.
|
Clin Infect Dis
|
2005
|
0.76
|
|
70
|
Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
|
Hum Vaccin Immunother
|
2014
|
0.76
|
|
71
|
Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).
|
AIDS Res Ther
|
2007
|
0.75
|
|
72
|
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.
|
Pediatr Infect Dis J
|
2017
|
0.75
|
|
73
|
Respiratory syncytial virus, antibiotics, and the critical care dilemma.
|
Pediatr Crit Care Med
|
2010
|
0.75
|
|
74
|
Opportunities to prevent HIV transmission in newborns.
|
Pediatrics
|
2006
|
0.75
|
|
75
|
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
|
Pediatr Infect Dis J
|
2016
|
0.75
|
|
76
|
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
|
Pediatr Infect Dis J
|
2016
|
0.75
|
|
77
|
Correlation of HIV-specific immunity, viral control, and diversification following planned multiple exposures to autologous HIV in a pediatric population.
|
Clin Vaccine Immunol
|
2011
|
0.75
|
|
78
|
Pediatric oncology: "an area of great change".
|
Pediatr Ann
|
2012
|
0.75
|
|
79
|
Neuroschistosomiasis due to Schistosoma haematobium presenting as spinal cord tumor.
|
Pediatr Infect Dis J
|
2011
|
0.75
|
|
80
|
Addressing and improving the continuum of care for HIV-affected children: challenges and solutions.
|
AIDS
|
2013
|
0.75
|
|
81
|
Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent.
|
Expert Rev Clin Pharmacol
|
2008
|
0.75
|
|
82
|
Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.
|
Pediatr Infect Dis J
|
2017
|
0.75
|
|
83
|
Less Common Pediatric Infectious Diseases Revisited.
|
Pediatr Ann
|
2017
|
0.75
|
|
84
|
A rational approach to the management of ventricular shunt infections.
|
Pediatr Infect Dis J
|
2005
|
0.75
|
|
85
|
Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndrome.
|
Pediatr Infect Dis J
|
2003
|
0.75
|
|
86
|
Developments in imaging: 'a huge difference in primary care'.
|
Pediatr Ann
|
2012
|
0.75
|
|
87
|
Evaluation of multiple drug therapy in human immunodeficiency virus-infected pediatric patients.
|
Pediatr Infect Dis J
|
2003
|
0.75
|
|
88
|
The glory of guidelines and the twilight of reality: controversies and challenges in the prevention and treatment of HIV in children.
|
Expert Rev Anti Infect Ther
|
2012
|
0.75
|